Certain medications originally developed for diabetes, cancer, and heart disease are now being studied for their potential to slow aging, improve healthspan, and reduce age-related decline.
In this section, we answer the most common questions about metformin, rapamycin, statins, ACE inhibitors, and experimental compounds like senolytics and FOXO4-DRI. Whether you're a researcher, biohacker, or simply curious — you'll find science-based insights into how these interventions may modulate aging at the molecular level.
Metformin is a diabetes medication that may extend lifespan by improving insulin sensitivity and mitochondrial health.
Learn more →
Some evidence suggests it may slow epigenetic aging and protect against age-related diseases.
Learn more →
It lowers glucose production in the liver and increases insulin sensitivity in tissues.
Learn more →
Some biohackers do, but research is ongoing and off-label use requires medical supervision.
Learn more →
Yes, it may blunt muscle adaptation to resistance training in some people.
Learn more →
Gastrointestinal upset, B12 deficiency, and rare lactic acidosis in susceptible individuals.
Learn more →
Paradoxically, it mildly inhibits mitochondrial complex I, which may trigger beneficial stress responses.
Learn more →
Yes, it reduces markers like CRP and TNF-alpha, supporting healthy aging pathways.
Learn more →
Several observational studies link metformin use to reduced risk of various cancers.
Learn more →
It can support hormonal balance in PCOS but may lower testosterone in men with long-term use.
Learn more →
Metformin targets metabolism and insulin pathways; rapamycin affects mTOR — they may be synergistic.
Learn more →
Doses vary — often 500–1000 mg/day is used off-label, with minimal effective dose preferred.
Learn more →
Some suggest cycling to avoid exercise interference and preserve metabolic flexibility.
Learn more →
Yes, the TAME trial (Targeting Aging with Metformin) is investigating its effects on lifespan and healthspan.
Learn more →
Yes, many longevity protocols use both for mitochondrial and metabolic support.
Learn more →
Yes, with long-term use. Regular monitoring and supplementation are recommended.
Learn more →
Possibly — it may enhance neurogenesis and reduce risk of cognitive decline.
Learn more →
Metabolic effects often begin within weeks; long-term aging benefits are gradual.
Learn more →
Generally well tolerated in healthy people, but it’s a prescription drug requiring supervision.
Learn more →
Rapamycin inhibits mTOR, a nutrient-sensing pathway linked to aging, promoting autophagy and cellular repair.
Learn more →
No, it’s approved for transplant immunosuppression; longevity use is off-label and experimental.
Learn more →
Rapamycin targets mTOR, while metformin affects AMPK and insulin pathways. They may be synergistic.
Learn more →
Animal studies show lifespan extension; human trials are ongoing (e.g., PEARL trial).
Learn more →
There’s no consensus. Low weekly dosing (e.g., 5–10 mg) is common in longevity circles.
Learn more →
Weekly dosing is preferred to reduce immunosuppression while maintaining anti-aging effects.
Learn more →
At transplant doses, yes. At low intermittent doses, it may boost immune surveillance in aging.
Learn more →
Mouth sores, elevated lipids, insulin resistance, or wound healing delay in some individuals.
Learn more →
Long-term safety in healthy people is not yet fully established — supervision is advised.
Learn more →
Animal studies suggest benefits in memory and neuroprotection; human data is limited.
Learn more →
It may suppress tumor growth and is being investigated for cancer prevention and treatment.
Learn more →
It can impair glucose tolerance in some users; combining with exercise or metformin may offset this.
Learn more →
It’s legal by prescription but not approved for anti-aging — considered off-label use.
Learn more →
Fasting, exercise, and compounds like berberine or spermidine also impact mTOR/AMPK balance.
Learn more →
Intermittent dosing shows promise in animals, but human trials will confirm safe protocols.
Learn more →
Yes, early studies suggest it may reduce signs of skin aging and senescent cell burden.
Learn more →
A clinical trial investigating rapamycin’s effect on aging biomarkers in healthy older adults.
Learn more →
Potentially. Combinations with metformin, NAD+ boosters, and statins should be monitored.
Learn more →
Via prescription (e.g., Sirolimus), usually from physicians specializing in preventative or anti-aging medicine.
Learn more →
Statins lower LDL cholesterol by inhibiting HMG-CoA reductase, a key enzyme in cholesterol synthesis.
Learn more →
They reduce cardiovascular mortality, but their benefit in primary prevention for longevity is debated.
Learn more →
Some experts argue they are, especially in people without cardiovascular disease.
Learn more →
Yes — including muscle pain, fatigue, liver enzyme elevations, and rarely cognitive changes.
Learn more →
Yes, they lower CRP and other inflammatory markers, which may contribute to their benefit.
Learn more →
Slightly, especially in people already at risk, due to effects on glucose metabolism.
Learn more →
Rarely, some users report brain fog or memory issues; most large trials show minimal cognitive effect.
Learn more →
Not necessarily — benefit depends on risk factors, biomarkers, and individual goals.
Learn more →
Yes — lifestyle, omega-3s, red yeast rice, berberine, and PCSK9 inhibitors in some cases.
Learn more →
Both reduce mortality — but exercise improves broader health domains including cognition and mobility.
Learn more →
Possibly through reduction in systemic inflammation and vascular aging.
Learn more →
Elevated LDL is linked to cardiovascular disease; its role in healthy aging remains debated.
Learn more →
Some evidence suggests statins may impair CoQ10 and energy production in sensitive individuals.
Learn more →
Yes — especially short-acting statins like simvastatin, due to nighttime cholesterol synthesis.
Learn more →
Supplementing CoQ10 may help alleviate muscle-related side effects in some users.
Learn more →
Via blood lipid panels, liver enzymes, CK (for muscle damage), and patient-reported symptoms.
Learn more →
Possibly, due to their anti-inflammatory effects — but personalized risk-benefit analysis is key.
Learn more →
Some users report reduced endurance or muscle strength — though not consistently observed.
Learn more →
Deprescribing may be appropriate in frail elderly or those with limited life expectancy — consult with a geriatrician.
Learn more →
They block angiotensin-converting enzyme, lowering blood pressure and reducing cardiovascular strain.
Learn more →
Some studies link ACE inhibitors with reduced mortality and improved cardiovascular aging.
Learn more →
Both protect the heart and kidneys; some studies favor ACE inhibitors for heart failure, others ARBs for side effect profile.
Learn more →
They improve endothelial function, reduce arterial stiffness, and lower oxidative stress.
Learn more →
Yes — especially in high-risk individuals or those with hypertension or diabetes.
Learn more →
Sometimes — in those with heart failure, kidney disease, or elevated vascular risk.
Learn more →
Cough, low blood pressure, dizziness, kidney function changes, or increased potassium.
Learn more →
Yes — they reduce intraglomerular pressure and are standard in diabetic nephropathy.
Learn more →
Blood pressure, electrolytes (especially potassium), and kidney function (creatinine, eGFR).
Learn more →
Some studies suggest better brain perfusion and reduced dementia risk vs. other antihypertensives.
Learn more →
Senolytics are compounds that selectively remove senescent cells, which contribute to aging and chronic disease.
Learn more →
FOXO4-DRI is a peptide that disrupts survival signaling in senescent cells, inducing apoptosis in dysfunctional cells.
Learn more →
In mice, yes. Human trials are still early, but promising for healthspan improvements.
Learn more →
Fisetin, quercetin, piperlongumine, and EGCG have senolytic properties in preclinical studies.
Learn more →
Biomarkers like p16INK4a, SASP factors, and imaging are used in research; no routine clinical test yet.
Learn more →
Intermittent "hit and run" dosing (e.g. monthly or quarterly) is used to minimize side effects.
Learn more →
Unknown in long term; some compounds may affect platelet function or cause transient fatigue.
Learn more →
Yes — UNITY's UBX1325, and Mayo Clinic–backed trials using Dasatinib + Quercetin.
Learn more →
In mice, yes. Human trials are ongoing to confirm safety and efficacy in aging-related diseases.
Learn more →
Yes, combinations with rapamycin, metformin, and NAD+ boosters are being explored for synergy.
Learn more →
Sign in to your account